RUNX1::RUNX1T1 (AML1::ETO) t(8;21) Detection, Quantitative

Also known as: AML1-ETO Q

Clinical Use

Use

This test is used to detect and quantify RUNX1::RUNX1T1 (AML1::ETO) fusion transcripts resulting from t(8;21), a recurrent genetic abnormality found in a subset of acute myeloid leukemia patients. It is beneficial for monitoring minimal residual disease and assessing the risk of relapse, aiding in the clinical management of patients diagnosed with this condition.

Special Instructions

Not provided.

Limitations

Translocations involving other genes or gene partners will not be detected. The limit of detection for this test is 1 in 100,000. Results should be interpreted within the clinical context of the patient and in conjunction with other relevant data. This test should not be used solely for diagnosing malignancy.

Test Details

New York Approved

Methodology

PCR-based (RT-PCR)

Biomarkers

RUNX1-RUNX1T1 fusion

Fusion

Concentration / Level

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Result Codes

21819-8 - t(8;21)(RUNX1T1,RUNX1) Bld/T Ql
21793-5 - t(8;21)(RUNX1T1,RUNX1) NFr Bld/T
21821-4 - t(9;22)(ABL1,BCR) Bld/T Ql

Result Turnaround Time

5-9 days

Specimen

Whole Blood

Volume

5 mL

Minimum Volume

3 mL

Container

Lavender (EDTA)

Storage Instructions

Refrigerate immediately.

Causes for Rejection

Serum, plasma, extracted DNA, CSF, FFPE tissue, ambient or frozen whole blood or bone marrow, and specimens in non-EDTA anticoagulants. Severely hemolyzed or clotted specimens and ambient bone marrow past 7 days.